Renal carcinoma
Conditions
Brief summary
Treatment patterns, including starting dose of Cabozantinib, dose interruption, dose modification related to all grade toxicity at 24 weeks.
Detailed description
Overall response rate based on radiological evaluation, Overall-survival, Progression free survival, Duration of response, Tolerance based on physicians and patients reports, Unplanned hospitalizations, emergency departments visits and falls, Patients reported quality of life (FACT-G and FACIT-TS-G),, Exploratory analyses to assess potential associations between G-CODE parameters and pharmacological monitoring of Cabozantinib with safety, efficacy, and QoL criteria
Interventions
DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.
Sponsors
Institut Gustave Roussy
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment patterns, including starting dose of Cabozantinib, dose interruption, dose modification related to all grade toxicity at 24 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall response rate based on radiological evaluation, Overall-survival, Progression free survival, Duration of response, Tolerance based on physicians and patients reports, Unplanned hospitalizations, emergency departments visits and falls, Patients reported quality of life (FACT-G and FACIT-TS-G),, Exploratory analyses to assess potential associations between G-CODE parameters and pharmacological monitoring of Cabozantinib with safety, efficacy, and QoL criteria | — |
Countries
France
Outcome results
None listed